Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
BJOG ; 129(2): 301-312, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-34651405

RESUMEN

OBJECTIVE: To assess the cost-effectiveness of prenatal detection of congenital cytomegalovirus (cCMV) following maternal primary infection in the first trimester within standard pregnancy follow-up or involving population-based screening (serological testing at 7 and 12 weeks of gestation), with or without secondary prevention (valaciclovir) in maternal CMV primary infection. DESIGN: Cost-effectiveness study from the perspective of the French national health insurance system. SETTING: Cost-effectiveness based on previously published probability estimates and associated plausible ranges hypothetical population of 1,000,000 pregnant women. POPULATION: Hypothetical population of 1,000,000 pregnant women. METHODS: Cost-effectiveness of detecting fetal cCMV in terms of the total direct medical costs involved and associated expected outcomes. MAIN OUTCOME MEASURES: Detection rates and clinical outcomes at birth. RESULTS: Moving to a population-based approach for targeting fetal CMV infections would generate high monetary and organizational costs while increasing detection rates from 15% to 94%. This resource allocation would help implementing horizontal equity according to which individuals with similar medical needs should be treated equally. Secondary prevention with valaciclovir had a significant effect on maternal-fetal CMV transmission and clinical outcomes in newborns, with a 58% decrease of severely infected newborns for a 3.5% additional total costs. Accounting for women decision-making (amniocentesis uptake and termination of pregnancy in severe cases) did not impact the cost-effectiveness results. CONCLUSIONS: These findings could fuel thinking on the opportunity of developing clinical guidelines to rule identification of cCMV infection and administration of in-utero treatment. These findings could fuel the development of clinical guidelines on the identification of congenital CMV infection and the administration of treatment in utero. TWEETABLE ABSTRACT: CMV serological screening followed by valaciclovir prevention may prevent 58% to 71% of severe cCMV cases for 38 € per pregnancy.


Asunto(s)
Infecciones por Citomegalovirus/diagnóstico , Complicaciones Infecciosas del Embarazo/diagnóstico , Diagnóstico Prenatal , Análisis Costo-Beneficio , Citomegalovirus/aislamiento & purificación , Infecciones por Citomegalovirus/sangre , Infecciones por Citomegalovirus/economía , Femenino , Francia , Humanos , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Programas Nacionales de Salud , Embarazo , Complicaciones Infecciosas del Embarazo/sangre , Complicaciones Infecciosas del Embarazo/economía , Primer Trimestre del Embarazo
2.
Clin Immunol ; 227: 108727, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-33887436

RESUMEN

With the global spread of coronavirus disease 2019 (COVID-19), the important role of natural killer (NK) cells in the control of various viral infections attracted more interest, via non-specific activation, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and activating receptors, as well as specific activation, such as memory-like NK generation. In response to different viral infections, NK cells fight viruses in different ways, and different NK subsets proliferate. For instance, cytomegalovirus (CMV) induces NKG2C + CD57 + KIR+ NK cells to expand 3-6 months after hematopoietic stem cell transplantation (HSCT), but human immunodeficiency virus (HIV) induces KIR3DS1+/KIR3DL1 NK cells to expand in the acute phase of infection. However, the similarities and differences among these processes and their molecular mechanisms have not been fully discussed. In this article, we provide a summary and comparison of antiviral mechanisms, unique subset expansion and time periods in peripheral blood and tissues under different conditions of CMV, HIV, Epstein-Barr virus (EBV), COVID-19 and hepatitis B virus (HBV) infections. Accordingly, we also discuss current clinical NK-associated antiviral applications, including cell therapy and NK-related biological agents, and we state the progress and future prospects of NK cell antiviral treatment.


Asunto(s)
COVID-19/inmunología , COVID-19/virología , Interacciones Microbiota-Huesped/inmunología , Células Asesinas Naturales/inmunología , Citotoxicidad Celular Dependiente de Anticuerpos , COVID-19/sangre , Citomegalovirus/inmunología , Infecciones por Citomegalovirus/sangre , Infecciones por Citomegalovirus/inmunología , Infecciones por Citomegalovirus/virología , Infecciones por Virus de Epstein-Barr/sangre , Infecciones por Virus de Epstein-Barr/inmunología , Infecciones por Virus de Epstein-Barr/virología , VIH/inmunología , Infecciones por VIH/sangre , Infecciones por VIH/inmunología , Infecciones por VIH/virología , Hepatitis B/sangre , Hepatitis B/inmunología , Hepatitis B/virología , Virus de la Hepatitis B/inmunología , Herpesvirus Humano 4/inmunología , Humanos , SARS-CoV-2/inmunología , Receptores Toll-Like/metabolismo
3.
J Pediatr Gastroenterol Nutr ; 67(5): 654-659, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-30074575

RESUMEN

OBJECTIVES: This study aimed to investigate the anti-human cytomegalovirus (CMV) activity of milk from seropositive and seronegative mothers of preterm infants and to analyze its changes throughout the different stages of lactation and after Holder pasteurization, a procedure adopted by donor human milk banks. METHODS: Eighteen mothers of preterm infants were enrolled in the study. Colostrum, transitional milk, and mature milk samples were collected and tested for anti-CMV activity. Depletion of immunoglobulins A from milk samples was carried out by jacalin resin. Pools of milk samples were pasteurized according to Holder technique. RESULTS: All samples were endowed with anti-CMV activity, although to a different extent. In CMV IgG-positive mothers, colostra were significantly more active than the transitional milk and mature milk samples. Moreover, they were more potent than colostra from seronegative mothers. Immunoglobulins A depletion in colostra from IgG-positive mothers resulted in a partial loss of anti-CMV activity. Holder pasteurization significantly reduced the antiviral activity. CONCLUSIONS: Human milk is endowed with anti-CMV activity and its potency may vary depending on the stage of lactation and the serological status of the mother. This biological property could partially neutralize CMV particles excreted in the milk of CMV IgG-positive mothers thus reducing the risk of transmitting infectious viruses to the infant.


Asunto(s)
Anticuerpos Antivirales/análisis , Calostro/inmunología , Infecciones por Citomegalovirus/inmunología , Citomegalovirus/inmunología , Leche Humana/inmunología , Adulto , Anticuerpos Antivirales/inmunología , Infecciones por Citomegalovirus/sangre , Infecciones por Citomegalovirus/transmisión , Femenino , Humanos , Inmunoglobulina A/análisis , Inmunoglobulina A/inmunología , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Recién Nacido , Recien Nacido Prematuro , Transmisión Vertical de Enfermedad Infecciosa , Masculino , Bancos de Leche Humana , Madres , Pasteurización
4.
Pediatr Nephrol ; 32(5): 879-884, 2017 05.
Artículo en Inglés | MEDLINE | ID: mdl-28039534

RESUMEN

BACKGROUND: New-onset diabetes after transplantation (NODAT) is a significant co-morbidity following kidney transplantation. Lower post-transplant serum magnesium levels have been found to be an independent risk factor for NODAT in adult kidney transplant recipients. METHODS: We undertook a retrospective analysis of risk factors for NODAT in pediatric renal transplant recipients at our institution with the aim of determining if hypomagnesemia confers a significant risk of developing NODAT in this patient population. RESULTS: A total of 173 children with a median age at transplantation of 7.0 (range 1.3-17.5) years were included. Hypomagnesemia was found to be a significant independent risk factor for NODAT (p = 0.01). High trough tacrolimus levels were also independently associated with NODAT (p < 0.001). There was no significant association between NODAT and body mass index at the time of transplantation, monthly cumulative steroid dose or post-transplant cytomegalovirus viremia (p = 0.9, 0.6 and 0.7, respectively). CONCLUSIONS: This study identifies hypomagnesemia as a significant independent risk factor for the development of NODAT in pediatric renal transplant recipients. Given the clear association between hypomagnesemia and NODAT in both adults and children following renal transplantation, further studies are merited to clarify the etiology of this association and to examine the effect of magnesium supplementation on NODAT.


Asunto(s)
Diabetes Mellitus/etiología , Trasplante de Riñón/efectos adversos , Deficiencia de Magnesio/complicaciones , Adolescente , Índice de Masa Corporal , Niño , Preescolar , Infecciones por Citomegalovirus/sangre , Infecciones por Citomegalovirus/complicaciones , Femenino , Humanos , Inmunosupresores/uso terapéutico , Lactante , Deficiencia de Magnesio/sangre , Masculino , Complicaciones Posoperatorias , Estudios Retrospectivos , Factores de Riesgo , Esteroides/efectos adversos , Esteroides/uso terapéutico , Tacrolimus/uso terapéutico , Receptores de Trasplantes
5.
An Pediatr (Barc) ; 82(1): e170-4, 2015 Jan.
Artículo en Español | MEDLINE | ID: mdl-24785445

RESUMEN

Cytomegalovirus infection is common in cardiac transplant patients. Foscarnet is used, with limited evidence, as second-line treatment after ganciclovir failure in these patients. We describe the case of a paediatric cardiac transplant patient who developed electrolyte disturbances during foscarnet treatment for cytomegalovirus infection. The infection resolved after 6 weeks of treatment. Low ionized calcium and magnesium levels were observed during the drug infusion, which were treated with supplements. The serum levels reverted to normal after drug withdrawal.


Asunto(s)
Antivirales/uso terapéutico , Calcio/sangre , Infecciones por Citomegalovirus/sangre , Infecciones por Citomegalovirus/tratamiento farmacológico , Foscarnet/uso terapéutico , Magnesio/sangre , Preescolar , Humanos , Masculino
6.
Environ Toxicol Pharmacol ; 37(3): 1140-7, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24802527

RESUMEN

Curcumin has been found to suppress the activity of human cytomegalovirus (HCMV) in vitro, whereas its protective effects against HCMV infection in vivo remain unclear. In this study, we aimed to investigate the protective effects of curcumin against HCMV infection in Balb/c mice. Mice were randomly divided into the control, model, model+ganciclovir (positive control), and model+high-dose, model+middle-dose, and model+low-dose curcumin groups. In the model groups, each mouse was given HCMV by tail injection intravenously. Positive control animals were given ganciclovir. Animals in the curcumin treatment groups were given different concentrations of curcumin. The anti-HCMV activities of ganciclovir and curcumin were assessed by serological examination and pathology. Ganciclovir and curcumin treatment reduced the HCMV IgM level and HCMV DNA load; decreased the serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine kinase (CK), and lactate dehydrogenase (LDH) as well as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) generation in infected mice. These treatments also suppressed malondialdehyde (MDA) content and upregulated superoxide dismutase (SOD) and glutathione (GSH) levels. In addition, both treatments prevented pathological changes of the lung, kidney, liver, and heart tissues in infected mice. Our findings indicate that curcumin protected Balb/c mice against HCMV infection possibly by its anti-inflammatory and antioxidant effects.


Asunto(s)
Antiinflamatorios/uso terapéutico , Antioxidantes/uso terapéutico , Curcumina/uso terapéutico , Infecciones por Citomegalovirus/tratamiento farmacológico , Alanina Transaminasa/sangre , Animales , Antiinflamatorios/farmacología , Antioxidantes/farmacología , Aspartato Aminotransferasas/sangre , Línea Celular , Creatina Quinasa/sangre , Curcumina/farmacología , Citomegalovirus/genética , Citomegalovirus/inmunología , Infecciones por Citomegalovirus/sangre , Infecciones por Citomegalovirus/patología , Infecciones por Citomegalovirus/virología , ADN Viral/análisis , Femenino , Glutatión/sangre , Corazón/efectos de los fármacos , Humanos , Inmunoglobulina M/sangre , Interleucina-6/sangre , Riñón/efectos de los fármacos , Riñón/patología , L-Lactato Deshidrogenasa/sangre , Hígado/efectos de los fármacos , Hígado/patología , Pulmón/efectos de los fármacos , Pulmón/patología , Masculino , Malondialdehído/sangre , Ratones Endogámicos BALB C , Miocardio/patología , Bazo/efectos de los fármacos , Bazo/patología , Superóxido Dismutasa/sangre , Factor de Necrosis Tumoral alfa/sangre
7.
Artículo en Inglés | MEDLINE | ID: mdl-15791862

RESUMEN

The aim of the study was to investigate the correlation between prognosis of human cytomegalovirus (HCMV) infection and zinc in mature women, in order to explore the effect of serum zinc on HCMV infection. 900 mature woman were examined for zinc level and serum HCMV specific antibodies (IgG and IgM). 63 HCMV-IgM positive cases were divided into 3 subgroups according to their serum zinc level, and HCMV-IgM was observed for conversion after treatment with a Chinese traditional medicine (Jinyebadu). Our results showed that the mean concentration of zinc in serum was significantly lower in HCMV-IgM(+) group than that in HCMV-IgM(-) group (P<0.001). A positive correlation was found between the response of mature females with HCMV infection to the treatment and the levels of serum zinc (P<0.001). The response of mature women with HCMV is poor when the serum zinc is lower than 0.70.


Asunto(s)
Anticuerpos Antivirales/sangre , Infecciones por Citomegalovirus/sangre , Citomegalovirus/inmunología , Zinc/sangre , Adulto , Antivirales/uso terapéutico , Infecciones por Citomegalovirus/tratamiento farmacológico , Medicamentos Herbarios Chinos/uso terapéutico , Femenino , Humanos , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Fitoterapia
9.
Int J Immunopharmacol ; 22(9): 729-40, 2000 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-10884593

RESUMEN

In this study, antiviral effect of black seed oil (BSO) from Nigella sativa was investigated using murine cytomegalovirus (MCMV) as a model. The viral load and innate immunity mediated by NK cells and Mφ during early stage of the infection were analyzed. Intraperitoneal (i.p.) administration of BSO to BALB/c mice, a susceptible strain of MCMV infection, strikingly inhibited the virus titers in spleen and liver on day 3 of infection with 1x10(5) PFU MCMV. This effect coincided with an increase in serum level of IFN-gamma. Although BSO treatment decreased both number and cytolytic function of NK cells on day 3 of infection, it increased numbers of Mφ and CD4(+) T cells. On day 10 of infection, the virus titer was undetectable in spleen and liver of BSO-treated mice, while it was detectable in control mice. Although spleen of both control and BSO-treated mice showed similar CTL activities on day 10 after infection, serum level of IFN-gamma in BSO-treated mice was higher. Furthermore, BSO treatment upregulated suppressor function of Mφ in spleen. These results show that BSO exhibited a striking antiviral effect against MCMV infection which may be mediated by increasing of Mφ number and function, and IFN-gamma production.


Asunto(s)
Infecciones por Citomegalovirus/inmunología , Infecciones por Citomegalovirus/prevención & control , Aceites de Plantas/farmacología , Plantas Medicinales , Animales , Antivirales/farmacología , Linfocitos T CD4-Positivos/efectos de los fármacos , Linfocitos T CD4-Positivos/inmunología , Infecciones por Citomegalovirus/sangre , Infecciones por Citomegalovirus/virología , Pruebas Inmunológicas de Citotoxicidad , Femenino , Citometría de Flujo , Interferón gamma/sangre , Interferón gamma/inmunología , Células Asesinas Naturales/efectos de los fármacos , Células Asesinas Naturales/inmunología , Hígado/virología , Macrófagos/efectos de los fármacos , Macrófagos/inmunología , Ratones , Ratones Endogámicos BALB C , Bazo/inmunología , Bazo/virología , Linfocitos T Citotóxicos/efectos de los fármacos , Linfocitos T Citotóxicos/inmunología , Carga Viral
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA